Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

GeneDx Holdings (WGS) EBT: 2020-2025

Historic EBT for GeneDx Holdings (WGS) over the last 6 years, with Sep 2025 value amounting to -$7.4 million.

  • GeneDx Holdings' EBT rose 11.62% to -$7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year increase of 102.98%. This contributed to the annual value of -$52.6 million for FY2024, which is 70.21% up from last year.
  • GeneDx Holdings' EBT amounted to -$7.4 million in Q3 2025, which was down 169.94% from $10.6 million recorded in Q2 2025.
  • GeneDx Holdings' EBT's 5-year high stood at $32.7 million during Q3 2021, with a 5-year trough of -$308.7 million in Q4 2022.
  • For the 3-year period, GeneDx Holdings' EBT averaged around -$21.1 million, with its median value being -$20.3 million (2024).
  • In the last 5 years, GeneDx Holdings' EBT surged by 157.81% in 2021 and then tumbled by 668.12% in 2022.
  • Quarterly analysis of 5 years shows GeneDx Holdings' EBT stood at -$40.2 million in 2021, then plummeted by 668.12% to -$308.7 million in 2022, then spiked by 91.52% to -$26.2 million in 2023, then surged by 120.68% to $5.4 million in 2024, then rose by 11.62% to -$7.4 million in 2025.
  • Its EBT stands at -$7.4 million for Q3 2025, versus $10.6 million for Q2 2025 and -$6.1 million for Q1 2025.